AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.
It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus.
In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement.
The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017.
ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Country | United States |
IPO Date | Oct 6, 2016 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 29 |
CEO | Paul F. Hickey |
Contact Details
Address: 1001 Calle Amanecer San Clemente, California United States | |
Website | https://www.reshapelifesciences.com |
Stock Details
Ticker Symbol | RSLS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001427570 |
CUSIP Number | 761123603 |
ISIN Number | US76090R2004 |
Employer ID | 00-0000000 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Mark B. Knudson Ph.D. | Co-Founder and Special Advisor to the Chief Executive Officer |
Paul F. Hickey | Chief Executive Officer, President & Director |
Thomas Stankovich | Senior Vice President & Chief Financial Officer |
Al Diaz | Vice President of Operations and R&D |
Dan W. Gladney | Executive Chair |
Dr. Dov Gal D.V.M., M.B.A. | Vice President of Regulatory Clinical Quality & Compliance Officer |
Dr. Katherine S. Tweden Ph.D. | Co-Founder |
Jody B. Dahlman | Director of Communications |
Naqeeb A. Ansari | Senior Vice President of Global Commercial Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 07, 2025 | SCHEDULE 13D | Filing |
Dec 27, 2024 | 8-K | Current Report |
Dec 20, 2024 | S-1 | Filing |
Dec 11, 2024 | 425 | Filing |
Dec 11, 2024 | 8-K | Current Report |
Dec 06, 2024 | S-4/A | [Amend] Filing |
Dec 02, 2024 | 8-K | Current Report |
Nov 14, 2024 | 8-K | Current Report |
Nov 14, 2024 | 10-Q | Quarterly Report |
Oct 17, 2024 | 8-K | Current Report |